Latest Aisling Capital Management LP Stock Portfolio
Aisling Capital Management LP Performance:
2025 Q4: 42.05%YTD: 148.29%2024: -20.16%
Performance for 2025 Q4 is 42.05%, and YTD is 148.29%, and 2024 is -20.16%.
About Aisling Capital Management LP and 13F Hedge Fund Stock Holdings
On 2026-02-10, the fund reported it's updated stock portfolio. In the 13F Holdings report, Aisling Capital Management LP reported an equity portfolio of $478.9 Millions as of 31 Dec, 2025.
The top stock holdings of Aisling Capital Management LP are BBIO, SNDX, GLUE. The fund has invested 81.3% of it's portfolio in BRIDGEBIO PHARMA INC. (BBIO) and 5.8% of portfolio in SYNDAX PHARMACEUTICALS, INC. (SNDX).
The fund managers got completely rid off VERONA PHARMA PLC (VRNA) (VRNA) and NUVATION BIO INC. (NUVB) (NUVB) stocks. They significantly reduced their stock positions in BRIDGEBIO PHARMA INC. (BBIO) (BBIO). Aisling Capital Management LP opened new stock positions in UROGEN PHARMA LTD. (URGN) (URGN).
The top stock holdings of Aisling Capital Management LP are BBIO, SNDX, GLUE. The fund has invested 81.3% of it's portfolio in BRIDGEBIO PHARMA INC. (BBIO) and 5.8% of portfolio in SYNDAX PHARMACEUTICALS, INC. (SNDX).
The fund managers got completely rid off VERONA PHARMA PLC (VRNA) (VRNA) and NUVATION BIO INC. (NUVB) (NUVB) stocks. They significantly reduced their stock positions in BRIDGEBIO PHARMA INC. (BBIO) (BBIO). Aisling Capital Management LP opened new stock positions in UROGEN PHARMA LTD. (URGN) (URGN).
Aisling Capital Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Aisling Capital Management LP made a return of 42.05% in the last quarter. In trailing 12 months, it's portfolio return was 148.29%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| urogen pharma ltd. (urgn) | 2,529,360 |
New stocks bought by Aisling Capital Management LP
Additions
Reductions
| Ticker | % Reduced |
|---|---|
| bridgebio pharma inc. (bbio) | -16.42 |
Aisling Capital Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| nuvation bio inc. (nuvb) | -10,954,400 |
| verona pharma plc (vrna) | -65,664,200 |
Aisling Capital Management LP got rid off the above stocks
Sector Distribution
Aisling Capital Management LP has about 95.8% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 95.8 |
| Others | 4.2 |
Market Cap. Distribution
Aisling Capital Management LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- MID-CAP
- SMALL-CAP
- MICRO-CAP
- UNALLOCATED
| Category | % |
|---|---|
| MID-CAP | 81.3 |
| SMALL-CAP | 8.7 |
| MICRO-CAP | 5.6 |
| UNALLOCATED | 4.2 |
Stocks belong to which Index?
About 93.9% of the stocks held by Aisling Capital Management LP either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
| Index | % |
|---|---|
| RUSSELL 2000 | 93.9 |
| Others | 6.1 |
Aisling Capital Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Aisling Capital Management LP
Aisling Capital Management LP has 13 stocks in it's portfolio. About 99.6% of the portfolio is in top 10 stocks. BMEA proved to be the most loss making stock for the portfolio. BBIO was the most profitable stock for Aisling Capital Management LP last quarter.
Last Reported on: 10 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACRS | aclaris therapeutics inc (acrs) | 0.27 | 434,455 | 1,307,710 | unchanged | 0.00 | ||
| BBIO | bridgebio pharma inc. (bbio) | 81.29 | 5,089,610 | 389,304,000 | reduced | -16.42 | ||
| BMEA | biomea fusion inc (bmea) | 0.53 | 2,048,760 | 2,540,460 | unchanged | 0.00 | ||
| CMPS | compass pathways plc (cmps) | 1.73 | 1,198,420 | 8,269,080 | unchanged | 0.00 | ||
| GLUE | monte rosa therapeutics inc (glue) | 4.82 | 1,472,330 | 23,086,200 | unchanged | 0.00 | ||
| MRKR | marker therapeutics, inc. (mrkr) | 0.10 | 325,370 | 484,801 | unchanged | 0.00 | ||
| NUVB | nuvation bio inc. (nuvb) | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| SNDX | syndax pharmaceuticals, inc. (sndx) | 5.78 | 1,316,810 | 27,666,100 | unchanged | 0.00 | ||
| SRRK | scholar rock holding corporation (srrk) | 0.71 | 77,031 | 3,393,220 | unchanged | 0.00 | ||
| URGN | urogen pharma ltd. (urgn) | 0.53 | 108,000 | 2,529,360 | new | |||
| VRNA | verona pharma plc (vrna) | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| bicara therapeutics inc. (bcax) | 2.00 | 568,919 | 9,574,910 | unchanged | 0.00 | |||
| bridgebio oncology therapeutics (bbot) | 1.48 | 564,625 | 7,069,100 | unchanged | 0.00 | |||
| calcimedica, inc. (calc) | 0.72 | 521,114 | 3,434,140 | unchanged | 0.00 | |||
| onkure therapeutics, inc. (okur) | 0.05 | 88,607 | 256,960 | unchanged | 0.00 | |||